Polyphenon E

Phase 2Small molecule

LLouisiana State University Health Sciences Center Shreveport

Polyphenon E is one of 255 small molecule programs targeting Toxicity. It is currently in Phase 2.

Indications

Total Trials

Active Trials

254

Competitors

Pipeline

Status by Indication[3][1]

Indication

ToxicityActive, not recruiting

Intraepithelial NeoplasiaActive, not recruiting

Chronic Obstructive Pulmonary DiseaseActive, not recruiting

Breast CancerActive, not recruiting

Prostate CancerActive, not recruiting

Chronic Lymphocytic LeukemiaActive, not recruiting

Small Cell Lung CancerActive, not recruiting

Ulcerative ColitisActive, not recruiting

Multiple SclerosisActive, not recruiting

ToxicityPhase 1

Active, not recruiting

Intraepithelial NeoplasiaPhase 2

Active, not recruiting

Chronic Obstructive Pulmonary DiseasePhase 2

Active, not recruiting

Breast CancerPhase 2

Active, not recruiting

Prostate CancerPhase 2

Active, not recruiting

Chronic Lymphocytic LeukemiaPhase 1/Phase 2

Active, not recruiting

Small Cell Lung CancerPhase 1

Active, not recruiting

Ulcerative ColitisPhase 2

Active, not recruiting

Multiple SclerosisPhase 1

Active, not recruiting

Competition

Competitive Landscape

2828 competitors in Breast Cancer

#DrugCompanyPhaseTrials

Polyphenon E

LLouisiana State University Health Sciences Center Shreveport

Phase 2

1 2

Cymbalta

Alnylam Pharmaceuticals

Preclinical

3 3

MS Contin

Merck & Co.

Preclinical

2 4

Zolymbus

AbbVie

Preclinical

1 5

Blenoxane

Bristol-Myers Squibb

Preclinical

1 6

Effexor

WWyeth-Lederle Vaccines

Preclinical

2 7

Tricor

JJagotec

Preclinical

1 8

Vit D

PPost Graduate Institute of Medical Education and Research, Chandigarh

Preclinical

1 9

Neoadjuvant Treatment

SShanghai Zhongshan Hospital

Preclinical

1 10

Diuretic

RReprieve Cardiovascular, Inc

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Chronic Obstructive Pulmonary Disease1 trial

Green Tea or Polyphenon E in Preventing Lung Cancer in Former Smokers With Chronic Obstructive Pulmonary Disease

Completed·SSherry Chow·Phase 2·NCT00363805·178 enrolled

Multiple Sclerosis1 trial

Safety of Polyphenon E in Multiple Sclerosis Pilot Study

Completed·LLouisiana State University Health Sciences Center in New Orleans·Phase 1·NCT00836719·10 enrolled

Ductal Carcinoma in Situ1 trial

A Pilot Study of Chemo-prevention of Green Tea in Women With Ductal Carcinoma in Situ

Terminated·UUniversity of Chicago·Phase 2·NCT01060345·20 enrolled

Chronic Lymphocytic Leukemia1 trial

Green Tea Extract in Treating Patients With Stage 0, Stage I, or Stage II Chronic Lymphocytic Leukemia

Completed·MMayo Clinic·Phase 1/2·NCT00262743·73 enrolled

Small Cell Lung Cancer1 trial

Study of Polyphenon E in Addition to Erlotinib in Advanced Non Small Cell Lung Cancer

Terminated·LLouisiana State University Health Sciences Center Shreveport·Phase 1·NCT00707252·11 enrolled

6 more indications

Toxicity1 trial

Study to Evaluate Safety and Toxicity of Polyphenon E (EGCG) in HIV-1-Infected Individuals

Completed·—·Phase 1·NCT01433289·23 enrolled

Completed·UUniversity of Louisville·Phase 2·NCT00718094·20 enrolled

Prostate Cancer1 trial

Green Tea Extract and Prostate Cancer

Completed·LLouisiana State University Health Sciences Center Shreveport·Phase 2·NCT00676780·33 enrolled

Sources

References

[1]
ClinicalTrials.gov — 11 trial records for Polyphenon E. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Polyphenon E compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Polyphenon E. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Louisiana State University Health Sciences Center Shreveport company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: LLouisiana State University Health Sciences Center Shreveport

Polyphenon E

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Chronic Obstructive Pulmonary Disease1 trial

Multiple Sclerosis1 trial

Ductal Carcinoma in Situ1 trial

Chronic Lymphocytic Leukemia1 trial

Small Cell Lung Cancer1 trial

Toxicity1 trial

Intraepithelial Neoplasia1 trial

Breast Cancer1 trial

Phase II1 trial

Ulcerative Colitis1 trial

Prostate Cancer1 trial

References

Drug Info

Quick Facts

Related News